Stocks / REGN
REGN stock forecast
REGENERON PHARMACEUTICALS INC · Healthcare · Biotechnology
Where this rating comes from: The Upfront Model, whose picks have been recorded with a fingerprint the day they publish since September 18, 2026. See the record.
In the model portfolio. REGN is holding #20 for 2026 Q4, at 1.7% of the book. See the portfolio
REGN against the S&P 500
| Period | REGN | S&P 500 (SPY) |
|---|---|---|
| 1 month | +20.9% | -4.7% |
| 3 months | +12.5% | -4.8% |
| Year to date | +23.0% | +7.9% |
| 1 year | +31.0% | +11.8% |
Total return, dividends included.
Key numbers
| Price | $945.53 |
| Market cap | 97.81 Billion |
| P/E (trailing 12 months) | 20.1 |
| P/S (trailing 12 months) | 5.8 |
| P/B (latest quarter) | 2.9 |
| Gross margin | 85.8% |
| Net profit margin | 28.5% |
| Return on equity | 15.1% |
| Beta | 0.4 |
As of October 30, 2026.
REGN and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| MRNA | MODERNA INC | 79.63 Billion | Greatly Underperform | REGN vs MRNA |
| VRTX | VERTEX PHARMACEUTICALS INC | 136.01 Billion | Outperform | VRTX vs REGN |
| INCY | INCYTE CORP | 24.01 Billion | Greatly Outperform | REGN vs INCY |
| TECH | BIO-TECHNE CORP | 11.43 Billion | Underperform | REGN vs TECH |
Questions
What does the Upfront Investment model say about REGN?
The model rates REGENERON PHARMACEUTICALS INC (REGN) "Outperform" as of November 18, 2026, which means its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the REGN rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is REGN in the Upfront Investment model portfolio?
Yes. REGN is holding number 20 in the 2026 Q4 model portfolio, at 1.7% of the book.
The rating is generated by The Upfront Model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.